Clinical trial
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2…
NCT00317720 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00317720 |
|---|---|
| Title | Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer |
| Official title | Phase I-II Study of Trastuzumab in Combination With RAD001 in Patients With HER-2 Overexpressing, PTEN-deficient Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Trastuzumab, RAD001 |
| Enrollment | 40 |
| Start date | Apr 1, 2006 |
| Primary completion | Feb 1, 2013 |
| Completion | Feb 1, 2013 |
| First posted | Apr 25, 2006 |
| Last update posted | Apr 30, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: